$Eli Lilly and Co (LLY.US)$ Eli Lilly Q2 FY24: Mounjaro, Zep...
$Eli Lilly and Co (LLY.US)$ Eli Lilly Q2 FY24:
Mounjaro, Zepbound, and Verzenio drive growth.
• Revenue +36% Y/Y to $11.3B ($1.3B beat).
• EPS $3.92 ($1.16 beat).
FY24 guidance (high end):
• Revenue +$3.0B to $46.6B.
• EPS +$0.29 to $14.00.
Mounjaro, Zepbound, and Verzenio drive growth.
• Revenue +36% Y/Y to $11.3B ($1.3B beat).
• EPS $3.92 ($1.16 beat).
FY24 guidance (high end):
• Revenue +$3.0B to $46.6B.
• EPS +$0.29 to $14.00.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
